Archives
SILENCE Randomized Trial: In patients at the end of life, prophylactic subcutaneous scopolamine butylbromide reduces the occurrence of the death rattle (noisy breathing caused by mucus in the upper respiratory tract).
6 Oct, 2021 | 09:54h | UTCEffect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of LifeThe SILENCE Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Preventing Death Rattle With Prophylactic Subcutaneous Scopolamine Butylbromide – JAMA (free for a limited period)
Author interview: Scopolamine Butylbromide for Preventing End-of-Life Death Rattle – JAMA
Commentary on Twitter
In a randomized clinical trial among patients near the end of life, prophylactic subcutaneous scopolamine butylbromide significantly reduced the occurrence of death rattle https://t.co/e6BDI5yirY pic.twitter.com/hHfhC2iYHh
— JAMA (@JAMA_current) October 5, 2021
Systematic review: Pretomanid for tuberculosis.
6 Oct, 2021 | 08:51h | UTCPretomanid for tuberculosis: a systematic review – Clinical Microbiology and Infection
Related:
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
WHO announces updated definitions of extensively drug-resistant tuberculosis
Supplement: Triumphs of Vaccination.
6 Oct, 2021 | 08:55h | UTCHomepage: Triumphs of Vaccination – The Journal of Infectious Diseases
Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease
The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease
Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe
Rubella Eradication: Not Yet Accomplished, but Entirely Feasible
Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster
Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication
Influenza Vaccines: Successes and Continuing Challenges
Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination
Overview of the United States’ Immunization Program
The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade
Review: Eosinophilic Esophagitis.
6 Oct, 2021 | 09:51h | UTCEosinophilic Esophagitis: A Review – JAMA (free for a limited period)
Related:
Clinical Guidelines for the Management of Eosinophilic Esophagitis
Eosinophilic Esophagitis: Review and Update
Is salt good for you after all? The evidence says no.
6 Oct, 2021 | 08:52h | UTCIs salt good for you after all? The evidence says no – The Conversation
Related:
Systematic Review: Altered dietary salt intake for people with chronic kidney disease.
New WHO benchmarks help countries reduce salt intake and save lives.
RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients
Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths
Meta-Analysis: Effect of Reduction in Dietary Sodium on Blood Pressure Levels
Review: Inhibition of platelet aggregation after coronary stenting in patients receiving oral anticoagulation.
6 Oct, 2021 | 08:46h | UTC
Series from the Lancet journals: Hematological malignancies in older people.
6 Oct, 2021 | 08:47h | UTCHomepage: Haematological malignancies in older people – The Lancet Haematology
Commentary: Living longer and better with haematological malignancies: a promise for older adults too? (free registration required)
A comprehensive approach to therapy of haematological malignancies in older patients (free registration required)
Frailty assessment in the care of older people with haematological malignancies
Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care (free registration required)
The diagnosis and management of endocrine side effects of immune checkpoint inhibitors.
6 Oct, 2021 | 08:44h | UTCRelated: Review: Endocrine complications of immunotherapies
Cohort study: Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older is rare, and most cases are not severe.
5 Oct, 2021 | 10:07h | UTCEditorial: COVID-19 Messenger RNA Vaccination and Myocarditis—A Rare and Mostly Mild Adverse Effect
Commentary on Twitter
New report on very rare acute myocarditis after mRNA vaccination in age 18+
5.8 cases/million after 2nd dose, 0.8/million 1st dose, all cases fully resolved with conservative managementhttps://t.co/Mfh5ImiSpW @KPSCALnews @KPSCalResearch @JAMAInternalMed— Eric Topol (@EricTopol) October 4, 2021
Imaging in non-bacterial osteomyelitis in children and adolescents: diagnosis, differential diagnosis and follow-up—an educational review based on a literature survey and own clinical experiences.
6 Oct, 2021 | 08:43h | UTC
Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.
5 Oct, 2021 | 10:09h | UTCCommentary: Expert reaction to study on Pfizer-BioNTech vaccine effectiveness up to 6 months – Science Media Centre
Commentary on Twitter
Study of 3.4 million people @aboutKP @TheLancet
Vaccine efficacy against infections:
– First month post: 88%
– 5 months post: 47%But vaccine efficacy against hospitalization (Figure):
– First month post: 87%
– 5 months post: 88 %https://t.co/1Gse0FKpoI pic.twitter.com/p9wyiaWGeg— Vincent Rajkumar (@VincentRK) October 4, 2021
RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.
5 Oct, 2021 | 10:06h | UTCRelated:
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
New Zealand acknowledges it can no longer completely get rid of the coronavirus.
5 Oct, 2021 | 10:02h | UTCNew Zealand acknowledges it can no longer completely get rid of the coronavirus – NPR
See also:
New Zealand admits it can no longer get rid of coronavirus – Associated Press
Battling Delta, New Zealand Abandons Its Zero-Covid Ambitions – The New York Times
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
5 Oct, 2021 | 09:57h | UTCA Pill For COVID? | A Doctor Explains Molnupiravir – ZDoggMD
COVID-19 and metabolic disease: mechanisms and clinical management.
5 Oct, 2021 | 10:03h | UTCRelated: Review | Interplay between endocrinology, metabolism, and COVID-19 infection.
Merck’s Covid-19 pill is great news but may not be a game-changer.
5 Oct, 2021 | 09:59h | UTCMerck’s Covid-19 pill is great news but may not be a game-changer – CNN
AAN Position Statement: Ethical perspectives on costly drugs and health care.
5 Oct, 2021 | 08:57h | UTCEthical Perspectives on Costly Drugs and Health Care: AAN Position Statement – Neurology
News release: AAN Issues Ethics Position Statement on Costly Drugs and Health Care – American Academy of Neurology
AHA Scientific Statement: Diagnosis and management of patients with myocardial injury after noncardiac surgery.
5 Oct, 2021 | 09:01h | UTCNews Release: 1 in 5 adults has high levels of heart enzymes after any surgery, monitoring advised – American Heart Association
Commentary: AHA: More Screening Needed to Catch Myocardial Injury After Noncardiac Surgery – TCTMD
Clinical practice guideline: evidence, recommendations and algorithm for the preoperative optimization of anemia, hyperglycemia and smoking.
5 Oct, 2021 | 08:59h | UTC
M-A: Beta-blockers do not reduce the risk of major adverse cardiovascular events in patients with stable coronary artery disease without prior myocardial infarction or left ventricular dysfunction.
5 Oct, 2021 | 08:53h | UTCMeta-Analysis of the Usefulness of Beta-Blockers to Reduce the Risk of Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease Without Prior Myocardial Infarction or Left Ventricular Dysfunction – The American Journal of Medicine (link to abstract – $ for full-text)
Intra-abdominal hypertension and abdominal compartment syndrome in critically ill patients: A narrative review of past, present, and future steps.
5 Oct, 2021 | 08:52h | UTC
Cohort study: Statin therapy initiation linked to increased risk of diabetes progression.
5 Oct, 2021 | 08:56h | UTCCommentaries:
Statin Therapy Initiation and Diabetes Progression – American College of Cardiology
Statin Initiation Linked to Greater Progression of Diabetes – HealthDay
Diabetes progression with initiation of statins – MedicalRessearch.com
Related:
Meta-Analysis: Medications that Reduce or Increase the Risk of New Onset Diabetes
Observational Study Points to an Increased Risk of Diabetes Among Patients Using Statins
Cohort Study: Statin Use Associated with a 38% Higher Risk of Incident Type 2 Diabetes
Commentary on Twitter
Large retrospective matched-cohort study found that #statin use was associated with a higher risk of #diabetes treatment escalation and an increased risk of #hyperglycemic complications https://t.co/lFLz7rVfpd
— JAMA Internal Medicine (@JAMAInternalMed) October 4, 2021
Review: Optimizing care for critically ill older adults.
5 Oct, 2021 | 08:51h | UTCOptimizing care for critically ill older adults – Canadian Medical Association Journal
Addressing Biased Patient Behavior: A Teachable Moment.
5 Oct, 2021 | 08:54h | UTCAddressing Biased Patient Behavior: A Teachable Moment – JAMA Internal Medicine
Podcast: Urinary Stone Disease.
5 Oct, 2021 | 08:50h | UTC#298 Urinary Stone Disease Will Rock Your World – The Curbsiders